New Zealand to purchase 10.7M doses of Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

December 17, 2020 -- The government of New Zealand has agreed to purchase 10.7 million doses of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

The vaccine candidate is currently being evaluated in a phase III clinical trial in the U.K. NVX-CoV2373 is a recombinant spike protein vaccine adjuvanted with Novavax's proprietary Matrix-M to enhance immune response.

Under the agreement, Novavax will manufacture NVX-CoV2373 with a target of delivering initial doses by mid-2021. The company will work with Medsafe, New Zealand's regulatory agency to obtain the necessary product approvals. Additional financial terms of the agreement were not disclosed.

Novavax provides updates on COVID-19 vaccine
Novavax has reported that it is making "meaningful progress" on its COVID-19 vaccine, NVX‑CoV2373.
Endo to provide fill-finish services for Novavax COVID-19 vaccine
Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's...
Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...
AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate...
Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...

Copyright © 2020 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter